A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Inclusion Criteria:

• Have completed Study AMAN (NCT03518086), with at least 1 study drug administrationand without early termination of study drug.

• Are willing and able to complete the scheduled study assessments, includingendoscopy and daily diary entry.

• If female, must meet the contraception requirements.

Exclusion Criteria:

• Participants diagnosed with Crohn's disease or inflammatory boweldisease-unclassified (indeterminate colitis) during the induction study AMAN (NCT03518086).

• Participants with a bowel resection or other surgery for the treatment of UC duringthe previous induction study AMAN (NCT03518086), or are likely to require surgeryfor the treatment of UC during study AMBG.

• Participants with evidence of colonic dysplasia or have been diagnosed with cancerof the gastrointestinal tract during study AMAN (NCT03518086).

• Participants diagnosed with clinically important infection including, but notlimited to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) duringthe induction study AMAN (NCT03518086).

• Participants who initiate a new prohibited medication during the induction studyAMAN (NCT03518086).

• Participants with certain laboratory abnormalities prior to start of AMBG that wouldrequire permanent discontinuation from study drug.